NCT00701649已完成2 期
A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 12
- 主要终点
- Adverse events: quality, quantity, severity
研究概览
简要总结
CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is administered by subcutaneous injection.
The objectives of the study are:
- To evaluate safety and tolerability of 5 s.c. injections of 300µg CYT006-AngQb with Alhydrogel™ in patients with mild to moderate essential hypertension (hypertension Grade I and II).
- To assess pharmacodynamic effects, i.e. anti-Ang II immune response and renin- angiotensin system (RAS) biomarkers.
- To explore the effect on blood pressure using ABPM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with mild to moderate essential hypertension (Grade I and Grade II) with mean sitting office SBP =140-179 mmHg and/or mean sitting office DBP = 90-109 mmHg on 2 consecutive visits (screening and V1).
- •Daytime blood pressure above threshold for definition of hypertension in the screening ABPM measurement (SBP >135 mmHg).
- •Patients without current antihypertensive therapy.
- •Patients on antihypertensive therapy, which can be stopped.
- •18 to 69 years of age.
- •Male patients, or female patients without childbearing potential .
排除标准
- •Patients with "very high added risk" according to 2007 Guidelines for the Management of Arterial Hypertension (Journal of Hypertension, 2007, 25:1105-1187), i.e. those with:
- •grade III hypertension (mean sitting office SBP ≥180mmHg and/or mean sitting DBP≥110mmHg)
- •history or presence of established cardiovascular or renal disease:
- •Ischemic stroke, cerebral hemorrhage, transient ischemic attack
- •Myocardial infarction, angina pectoris, coronary re-vascularization, heart failure
- •Peripheral artery disease
- •Diabetic nephropathy
- •Known autoimmune disease.
- •Severe allergy.
- •Pregnancy or breastfeeding.
- •Women in childbearing age that are not surgically sterilized.
- •Patients with a history or current positive test for HIV infection, AIDS, or other immunosuppressive disorders; hepatitis B or C.
- •Current diagnosis or history of malignancy.
- •Presence of suspicious lymphadenopathy or splenomegaly on physical examination.
- •Drug or alcohol abuse within the past 2 years.
- •Presence or history of relevant cardiovascular, renal, hepatic, pulmonary, endocrine, autoimmune, neurological and psychiatric disease as judged by the investigator.
- •Any current or past disease or conditions (physical or mental) that would, in the opinion of the investigator, interfere with the study procedures or interpretation of the study data (e.g. workers in the night shift).
- •Previous participation in a clinical trial with a Qb based vaccine.
- •Use of an investigational drug within 3 months before enrolment, or planned use during the whole study period.
- •Possible dependency of the patient on sponsor and/or investigator.
- •Planned active immunization 2 weeks before or 2 weeks after any study medication vaccination.
- •Donation or loss >=400 mL of blood within 8 weeks prior to dosing or major surgery within past 2 months.
结局指标
主要结局
Adverse events: quality, quantity, severity
时间窗: Throughout the study until week 48
次要结局
- Change in daytime, nighttime and 24-hour ambulatory blood pressure from baseline(24 hours)
- Titer of IgG specific for angiotensin II(Throughout the study untill week 48)
- Amount of RAS-Biomarkers (plasma renin concentration, angiotensin II, aldosterone)(24 hours)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Safety, Tolerability and Efficacy of a Vaccine Against Essential HypertensionMild Essential HypertensionModerate Essential HypertensionNCT00710372Cytos Biotechnology AG83
已完成
1 期
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult VolunteersPulmonary TuberculosisNCT01927159Access to Advanced Health Institute (AAHI)66
已完成
1 期
Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV VaccineHIV InfectionNCT00482027International AIDS Vaccine Initiative80
已完成
2 期
A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older AdultsHealthyNCT04453202Janssen Vaccines & Prevention B.V.459
已完成
3 期
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY VaccineMeningitis, MeningococcalNCT04707391GlaxoSmithKline1,250